News

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...
TMCnet16d

Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors

Designed to support clinicians with same-day assessments, the platform aims to improve outcomes while reducing reliance on subjective evaluation. Supported by BARDA and classified as a Breakthrough ...
The Daily Star4d

Looking at the July uprising through Actor-Network Theory

What emerged in July-August 2024 was a perfect storm—not in the metaphorical sense of a rare confluence of disasters but, in ...

USA News Group: Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 7, 2025 /PRNewswire/ -- USA News Group News Commentary - This week in Geneva, the World Health ...

Neurofibromatosis Type 2 Market Set For Robust Growth Through 2034, Driven By Promising Pipeline Developments Delveinsight

Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...
GEN - Genetic Engineering and Biotechnology News15d

Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Shifting trajectory of financial markets and trading in the AI age

Amid the evolving trading models and market platforms, the fundamental construct of financial markets—to conclude transactions between anonymous or known counterparties—has largely remained unchanged ...